Skip to main content

AgomAb Therapeutics NV

AGMB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0002020932

In the last 90 days, AgomAb Therapeutics NV insiders filed 7 open-market purchases and 0 sales; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.

Key figures

Market capADS ratio not in SEC data
–
Insider buysLast 90 days, $592.1K in total
7
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +2 vs. previous quarter
34
13F valueReported value at the end of Q2 2026
$337.0M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
920.9K
Shares sold short
Change
−21.1K
−2.2% vs. previous
Days to cover
7.44
At average daily volume

Superinvestors holding AGMB, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding AGMB at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by AgomAb Therapeutics NV insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)6:43 AM ETNov 133 daysEpstein David RDirectorPPurchase+15.0K$5.92+$88.7K+37.5%55.0K after4 lots
Nov 6, 2026 (view filing)6:39 AM ETNov 51 dayEpstein David RDirectorPPurchase+15.0K$6.90+$103.5K+60.0%40.0K after3 lots
Oct 22, 2026 (view filing)8:14 AM ETOct 211 dayEpstein David RDirectorPPurchase+10.0K$8.88+$88.8K+66.7%25.0K after2 lots
Oct 9, 2026 (view filing)8:01 AM ETOct 81 dayEpstein David RDirectorPPurchase+5.00K$8.90+$44.5K+50.0%15.0K after
Oct 7, 2026 (view filing)8:57 AM ETOct 5-62 daysEpstein David RDirectorPPurchase+10.0K$8.64+$86.3KNew position10.0K after2 lots
Oct 7, 2026 (view filing)8:47 AM ETOct 61 dayKemula Pierre Thadee VictorChief Financial OfficerPPurchase+10.0K$8.59+$85.9KNew position10.0K after3 lots
Oct 7, 2026 (view filing)8:06 AM ETOct 5-62 daysKnotnerus Tim JasperChief Executive OfficerPPurchase+11.0K$8.58+$94.4K+101.6%21.8K after2 lots

Top 10 13F holders, Q2 2026

See all 34 holders

The largest institutional positions in AgomAb Therapeutics NV at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding AGMB in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
EQT Fund Management S.a r.l.5,141,992$66.7M7.74%00.0%Unchanged
Sanofi2,783,096$36.1M6.76%00.0%Unchanged
Redmile Group, LLC2,733,926$35.5M2.38%+2,577,676+1,649.7%Added
Cormorant Asset Management, LP2,465,348$32.0M1.64%00.0%Unchanged
TCG Crossover Management, LLC2,053,233$26.7M0.64%00.0%Unchanged
Federated Hermes, Inc.1,618,000$21.0M0.03%00.0%Unchanged
Nantahala Capital Management, LLC1,568,188$20.4M1.23%+368,188+30.7%Added
Casdin Capital, LLC1,550,000$20.1M1.01%00.0%Unchanged
Andera Partners1,538,702$20.0M9.67%00.0%Unchanged
FMR LLC1,458,677$18.9M0.00%00.0%Unchanged

Holders of 5% or more of AGMB

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of AgomAb Therapeutics NV.

Largest holders of AGMB from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
LSP 7 Cooperative UA13D10.60%5.14M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC
FMR LLC13G10.00%4.87M sharesNewMar 6, 20261 filingMar 6, 2026SEC
Pontifax Management 4 G.P. (2015) Ltd.13G6.80%3.31M sharesNewApr 16, 20261 filingApr 16, 2026SEC
Sanofi13G5.71%2.78M sharesNewMay 6, 20261 filingMay 6, 2026SEC
Cormorant Asset Management, LP13G5.01%2.47M sharesNewMay 15, 20261 filingMay 15, 2026SEC